| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
35,138 |
28,406 |
$1.21M |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
6,669 |
6,171 |
$259K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
3,623 |
3,296 |
$242K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
16,166 |
7,588 |
$210K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
2,499 |
2,248 |
$169K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
2,286 |
2,024 |
$138K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
14,875 |
7,251 |
$123K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
7,601 |
7,171 |
$99K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
1,257 |
1,140 |
$97K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,834 |
1,693 |
$92K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
557 |
510 |
$73K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,142 |
1,083 |
$62K |
| 87807 |
|
3,510 |
3,254 |
$37K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
4,809 |
4,380 |
$34K |
| 99050 |
|
1,901 |
1,757 |
$27K |
| 90461 |
|
5,681 |
4,321 |
$26K |
| 92587 |
|
4,780 |
4,193 |
$25K |
| 99381 |
|
477 |
418 |
$24K |
| 85018 |
|
8,033 |
7,142 |
$15K |
| 99383 |
|
172 |
163 |
$14K |
| 80061 |
Lipid panel |
1,148 |
1,030 |
$11K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
152 |
119 |
$10K |
| 83655 |
|
1,113 |
919 |
$9K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
725 |
559 |
$8K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,227 |
1,090 |
$8K |
| 97802 |
|
2,744 |
2,256 |
$6K |
| 92551 |
|
608 |
602 |
$6K |
| 99401 |
|
2,337 |
1,810 |
$5K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
86 |
84 |
$4K |
| 99382 |
|
46 |
45 |
$4K |
| 99384 |
|
33 |
32 |
$3K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
296 |
276 |
$3K |
| 82947 |
|
987 |
907 |
$3K |
| 99000 |
|
898 |
836 |
$3K |
| 96127 |
|
1,272 |
1,133 |
$2K |
| 69210 |
|
46 |
45 |
$2K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
38 |
38 |
$1K |
| 36415 |
Collection of venous blood by venipuncture |
5,858 |
5,521 |
$945.00 |
| 90649 |
|
93 |
75 |
$560.00 |
| 81002 |
|
193 |
182 |
$539.04 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
239 |
173 |
$281.17 |
| 90677 |
|
375 |
269 |
$241.23 |
| 90670 |
|
2,153 |
2,002 |
$140.00 |
| 90700 |
|
462 |
453 |
$122.50 |
| 90633 |
|
1,422 |
1,334 |
$122.50 |
| 90686 |
|
1,696 |
1,602 |
$72.87 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
117 |
96 |
$70.75 |
| 96161 |
|
876 |
835 |
$17.50 |
| 36416 |
|
2,934 |
2,387 |
$8.75 |
| 90681 |
|
738 |
680 |
$0.00 |
| 99051 |
|
583 |
548 |
$0.00 |
| 99173 |
|
4,631 |
4,186 |
$0.00 |
| 90648 |
|
1,557 |
1,385 |
$0.00 |
| 90707 |
|
533 |
501 |
$0.00 |
| 90710 |
|
592 |
538 |
$0.00 |
| 90734 |
|
522 |
480 |
$0.00 |
| 90715 |
|
245 |
235 |
$0.00 |
| 90723 |
|
916 |
800 |
$0.00 |
| 90716 |
|
556 |
524 |
$0.00 |
| 90698 |
|
567 |
546 |
$0.00 |
| 90650 |
|
39 |
39 |
$0.00 |
| 90696 |
|
534 |
487 |
$0.00 |
| 90744 |
|
118 |
113 |
$0.00 |
| 90657 |
|
38 |
38 |
$0.00 |
| 90651 |
|
53 |
51 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
14 |
13 |
$0.00 |
| 90697 |
|
45 |
36 |
$0.00 |